Stock Price Forecast

Feb. 7, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading AgeX Therapeutics Inc chart...

About the Company

AgeX Therapeutics, Inc. iis focused on developing and commercializing innovative therapeutics for human aging. Its PureStem® and UniverCyte™ manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX's revolutionary longevity platform induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

CEO

Michael West

Exchange

NYSE MKT LLC

Website

www.agexinc.com

$0M

Total Revenue

8

Employees

$27M

Market Capitalization

-2.39

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AGE News

AgeX Therapeutics Inc

11d ago, source: Reuters

AgeX Therapeutics Inc. is a biotechnology company that is focused on the development and commercialization of therapeutics targeting human aging and degenerative diseases. The Company's product ...

Juvenescence Cuts Stake in AgeX Therapeutics

8d ago, source: 24/7 Wall St

Fintel reports that Juvenescence Ltd has filed a 13D/A form with the SEC disclosing ownership of 57.08MM shares of AgeX Therapeutics Inc (AGE). This represents 72.6% of the company. In their previous ...

Verve Therapeutics Inc.

6d ago, source: Wall Street Journal

1 Day VERV 8.79% DJIA -0.11% S&P Mid Cap 400 1.16% Health Care/Life Sciences 0.63% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent ...

Axsome Therapeutics Inc (AXSM)

1d ago, source: Investing

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

VistaGen Therapeutics Stock (NASDAQ:VTGN), Quotes and News Summary

1d ago, source: Benzinga.com

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders ...

Revance Therapeutics, Inc. (RVNC) Soars 8.6%: Is Further Upside Left in the Stock?

15d ago, source: Yahoo

Revance Therapeutics, Inc. RVNC shares rallied 8.6% in the last trading session to close at $31.70. This move can be attributable to notable volume with a higher number of shares being traded than ...

AgeX Therapeutics Inc (AGE)

4d ago, source: Investing

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

AgeX Therapeutics, Inc. (AGE)

4d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

AGE AgeX Therapeutics, Inc.

19d ago, source: Seeking Alpha

**NM signifies a non meaningful value. A dash signifies the data is not available.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...